课题基金 / 基金详情

Identification of antigen for cause of ITP by the new molecular biological method (SEREX)

Identification of antigen for cause of ITP by the new molecular biological method (SEREX)
通过新分子生物学方法(SEREX)鉴定 ITP 病因抗原
批准号:
10670943
负责人:
WADA Hideo
金额:
$0.64万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1998
资助国家:
日本
项目状态:
已结题
起止时间:
1998 至 1999

项目摘要

项目成果

WADA Hideo的其他基金

相似基金

相关文献

中文摘要
翻译
为明确特发性血小板减少性紫癜(ITP)特异性抗原的病因,采用高灵敏度基因克隆方法直接分析ITP特异性抗原基因,采用重组表达克隆方法(SEREX)进行抗原血清学鉴定。我们从UT-7/血小板生成素中提取RNA并制备cDNA。将该cDNA在大肠杆菌中表达后,获得38个与ITP患者血清反应的克隆。其中9个克隆为未知克隆,19个克隆为已知克隆。我们重点研究人丁型肝炎抗原相互作用蛋白A(dip A),因为它对ITP血清有强烈反应。用RT-PCR方法检测dip A在所有细胞系中的表达。用免疫印迹法检测ITP患者血清中抗dip A抗体。60%的ITP患者dip A抗体阳性,而健康志愿者仅20%阳性。dip-A基因点突变的可能性及抗dip-A抗体在ITP发病中的作用有待进一步研究。
英文摘要
To identify the cause of specific antigen in idiopathic thrombocytopenic purpura (ITP), we directly analyzed the gene of specific antigen in ITP by high sensitivity of genetic cloning method ; serological identification of antigens by recombinant expression cloning (SEREX). We extracted the RNA from UT-7/thrombopoietin and made the cDNA. After expression of protein from the cDNA in E-Coli, 38 clones which were reacted to the serum of patients with ITP were obtained. Out of them, 9 clones were unknown and 19 were known by the analysis of sequence of gene. We focused human hepatitis delta antigen interacting protein A (dip A), because it strongly reacted to the ITP serum. By RT-PCR method, we detected the expression of dip A in all cell line. We examined the anti-dip A antibody in patients with ITP by western blot method. Sixty percent of ITP patients were positive for dip A antibody, but only 20% of healthy volunteers were positive. The possibility of point mutation in dip-A and role of anti-dip-A antibody in the onset of ITP should be studied furthermore.
期刊论文(24)
专著(0)
科研奖励(0)
会议论文
Wakita Y, et al.: "Increased plasma tissue factor antigen levels in patients positive for lupus Anticoagulant"Clin Appl Thromb Hemastas. 5(1). 10-15 (1999)
Wakita Y 等人:“狼疮抗凝剂阳性患者血浆组织因子抗原水平升高”Clin Appl Thromb Hemastas。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Mori Y, et al.: "Outcome of thrombic thrombocytopenic purpura and hemolytic uremic syndrome in Japan"Clin Appl Thromb Hemastas. 5(2). 110-112 (199)
Mori Y 等人:“日本血栓性血小板减少性紫癜和溶血性尿毒症综合征的结果”Clin Appl Thromb Hemastas。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Mori Y,et al: "Outcome of thrombotic thrombocytopenic purpura and hemolytic ceramic cyndrome in Japan"Clin Appl Thromb Hemostas. 5・(2). 110-112 (1999)
Mori Y等人:“日本血栓性血小板减少性紫癜和溶血陶瓷综合征的结果”Clin Appl Thromb Hemostas 5·(2)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Mari Y, et al.: "Out*me of thrombolic th*abosytopenic purpura and hemalytic uremic cyndrone in Japan"Clin Appl Thromb Hemostas. 5・(2). 110-112 (1999)
Mari Y等人:“日本的血栓性贫血性紫癜和溶血性尿毒症综合症”Clin Appl Thromb Hemostas 5・(2)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
24
    Monitoring for anticoagulant therapy and mechanism for anticoagulant
    • 批准号:
      24590692
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.41万
    • 财政年份:
      2012
    • 负责人:
      WADA Hideo
    • 依托单位:
    Study on early diagnosis of hypercoagulable state and mechanism for the onset in thrombosis
    • 批准号:
      21590623
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.16万
    • 财政年份:
      2009
    • 负责人:
      WADA Hideo
    • 依托单位:
    Analysis of mechanism on enhancement of fibrinolysis as biological defense
    • 批准号:
      13470519
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $6.46万
    • 财政年份:
      2001
    • 负责人:
      WADA Hideo
    • 依托单位:
    RELATIONSHIP BETWEEN VASCULAR ENDOTHELIAL CELL INJURIES AND RED CELL FRAGMENTATION SYNDROME
    • 批准号:
      06671086
    • 项目类别:
      Grant-in-Aid for General Scientific Research (C)
    • 资助金额:
      $1.41万
    • 财政年份:
      1994
    • 负责人:
      WADA Hideo
    • 依托单位:
    国内基金
    海外基金
    基于SEREX技术筛选的自身抗原FTL在免疫相关性全血细胞减少症中的作用研究
    • 批准号:
      81600088
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      18.0万元
    • 批准年份:
      2016
    • 负责人:
      郝山凤
    • 依托单位:
    SEREX筛选骨肉瘤特异性抗原并应用于免疫治疗